Search

Your search keyword '"Bompas E"' showing total 385 results

Search Constraints

Start Over You searched for: Author "Bompas E" Remove constraint Author: "Bompas E"
385 results on '"Bompas E"'

Search Results

1. Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma

2. Improved nationwide survival of sarcoma patients with a network of reference centers

3. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years

4. Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years

5. VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

8. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

9. 52O Resistance to imatinib induced by treatment interruption in advanced GIST: Long-term outcome of the randomized BFR14 study

10. 55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

11. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

12. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

13. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years

14. Surgery in reference centers improves survival of sarcoma patients: a nationwide study

16. Improved survival using specialized multidisciplinary board in sarcoma patients

17. Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age

20. 1512P Pain in patients with desmoid fibromatosis (DF)

21. 1316O Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network

22. 1515P Nationwide management of soft tissue sarcoma (STS) in France, before (2019) versus during COVID-19 pandemic (2020)

24. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group

25. Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group

29. 1522MO Hormonal contraception and pregnancy and risk of progression or relapse in desmoid-type fibromatosis (DF)

30. 1524MO Patterns of care and outcomes of 64 CIC-rearranged sarcoma: A retrospective multicentre case-series within the French Sarcoma Group (FSG)

31. 1530P Outcome of primary soft tissue or bone myoepithelial tumors (METs)

32. 822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy

33. 1544P Soft tissue sarcoma (STS) incidences and clinical characteristics are significantly different between different geographic and ethnic populations

34. 603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial

35. LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

40. 1913O A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study

43. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group

44. Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE†

49. LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER

50. 1636P METASYN: Patterns of care and outcomes of 387 METAstatic SYNovial sarcoma: Real-life data from the French Sarcoma Group (GSF/GETO)

Catalog

Books, media, physical & digital resources